Corbus (CRBP) news
Recent news
Corbus Pharmaceuticals Holdings Inc: expects to initiate enrollment in Tempo-1 in September 2026
AInvest Wire · Jul 28, 2026Corbus Pharmaceuticals announces FDA clearance to initiate Tempo-1 registrational study of CRB-701 in patients with 2L oropharyngeal cancer
AInvest Wire · Jul 28, 2026Corbus Pharmaceuticals appoints Leonardo Viana Nicacio, M.D. as chief medical officer
Corbus Pharmaceuticals has announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, effective immediately . Dr. Nicacio brings extensive experience in oncology, drug development, and regulatory affairs, having held leadership roles at companies such as Stemline…
AInvest Wire · Jul 6, 2026Corbus Pharmaceuticals Holdings Inc: Mizuho cuts target price to $34 from $44
Mizuho Securities recently adjusted its price target for Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), lowering it to $34 from $44 while maintaining an Outperform rating. The firm cited updated assumptions for key drug candidates, including CRB-701 and CRB-913, as the primary reason for the…
AInvest Wire · Jun 23, 2026Corbus Pharmaceuticals Holdings: Oppenheimer cuts target price to $52 from $54
Oppenheimer has lowered its price target for Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) to $53.00 from $60.00, while maintaining an Outperform rating . The stock is currently trading at $12.26, significantly below the analyst consensus range of $28–$55. The adjustment follows the firm’s…
AInvest Wire · Jun 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.